Company: HROW
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021562
Chunk: 66

Company: HARROW, INC.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 1
Chunk 66
---
 on extinguishment of debt of $7,750,000, related to the payoff
of the 2026 Notes and 2027 Notes along with the Oaktree Loan. There were no extinguishments of debt during the three and nine months
ended September 30, 2024.

36

Liquidity
and Capital Resources

Liquidity

Our
cash on hand at September 30, 2025 was $74,290,000, compared to $47,247,000 at December 31, 2024.

As
of the date of this Quarterly Report, we believe that cash and cash equivalents of $74,290,000 at September 30, 2025 will be sufficient
to sustain our planned level of operations and capital expenditures for at least the next 12 months.

In
addition, we may consider the sale of certain assets. However, we may pursue acquisitions of products, drug candidates or other strategic
transactions that involve large expenditures or we may experience growth more rapidly or on a larger scale than we expect, any of which
could result in the depletion of capital resources more rapidly than anticipated and could require us to seek additional financing to
support our operations.

We
expect to use our current cash position and funds generated from our operations and any financing to pursue our business plan, which
includes developing and commercializing drug candidates, compounded formulations and technologies, integrating and developing our operations,
pursuing potential future strategic transactions as opportunities arise, including potential acquisitions of additional drug products,
drug candidates, and/or assets or technologies, pharmacies, outsourcing facilities, drug company and manufacturers, and otherwise fund
our operations and potential future milestone payments. We may also use our resources to conduct clinical trials or other studies in
support of our formulations or any drug candidate for which we pursue FDA approval, to pursue additional development programs or to explore
other development opportunities.

Net
Cash Flow

The
following provides detailed information about our net cash flows for the nine months ended September 30, 2025 and 2024:

    For the Nine Months Ended September 30, 

    2025  
    2024 
  
    Net cash provided by (used in): 

    Operating activities 
    $35,453,000  
    $(4,423,000)
  
    Investing activities 
     (730,000) 
     4,396,000 
  
    Financing activities 
     (7,680,000) 
     (